UNC Lineberger Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, UNC Lineberger Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count).
UNC Lineberger Comprehensive Cancer Center: 366 sponsored US clinical trials, 79 recruiting.
UNC Lineberger Comprehensive Cancer Center sponsors 366 registered US clinical trials on ClinicalTrials.gov, 79 of them currently recruiting, and 209 completed. 2 of these trials are in Phase 3-4 (later-stage) and 157 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 29 trials.
Top-decile sponsor footprint
UNC Lineberger Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#97 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
209 of 246 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
366 total, page 3 of 8
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
NCT02690545
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
NCT02663297
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
NCT03016377
Improving Affordability in Cancer Care Through Economic Screening and Support (I-ACCESS)
NCT07664436
Optimization of Dietary Adherence in a Mobile Weight Loss Intervention
NCT07582536
Evaluation of Impact of AI Assistance on Workload Associated w Preparation of Rare Tumor Case Repts
NCT06026098
Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT
NCT05937659
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
NCT07078838
The PharmFIT Study
NCT06656936
Overcoming Barriers to Uptake of Cascade Screening
NCT07304063
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
NCT07685938
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors
NCT07526597
Virtual Testis Cancer Lay Support and Survivorship Aim 2
NCT06702592
SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent
NCT07494994
Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
NCT07605949
Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)
NCT07634653
Effects of Infusion Timing on Treatment Response in Solid Tumors
NCT07630168
C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States
NCT07520188
Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
NCT07639242
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
NCT07484139
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
NCT05751993
Social Media Posts About Cancer: Five Timepoints
NCT07588607
VisR for Noninvasively Interrogating Stromal Collagen Organization as a Breast Cancer Biomarker: Evaluation of Compression in Control Subjects
NCT06547034
Effective Ads for Quitting Smoking
NCT06485479
Little Cigar and Cigarillo Warnings to Reduce Tobacco-Related Cancers and Disease - Eye Tracking
NCT06546618
Little Cigar and Cigarillo Warnings for Youth
NCT06413797
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
NCT05911308
Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors
NCT06171945
Impact of E-Cigarette Prevention Messages on Adolescents
NCT05985538
Physical Activity and Healthy Eating Among Young Adult Cancer Survivors
NCT05887401
Physical Therapy in Pre-cystectomy Patients
NCT05978570
Little Cigar and Cigarillo Warnings Among US Adults Who Use LCCs
NCT05849051
enCompass Carolina: A Social Support and Coaching Program for Cancer Caregivers
NCT05828927
Intervention to Address Psychosocial Needs Among Socially Disadvantaged Older Adults With Cancer
NCT05828654
Assessing Functional Status Needs Via PRO Measures for Pts With Metastatic Breast Cancer
NCT05755347
Risk Stratification for Patients With Hospital-diagnosed Advanced Lung Cancer
NCT05722847
Engaging Clinical Champions to Improve HPV Vaccination
NCT05736718
Impact of E-cigarette Device Warnings
NCT05714982
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
NCT05630131
Impact of Physical and Occupational Therapy in New BMT Patients
NCT05978583
CD30 CAR for CD30+ NSGCT
NCT05634785
Physical Function During ARSI Treatment
NCT05612880
Metastatic Breast Cancer-Specific Prognostic Tool
NCT05574478
The Families Addressing Cancer Together Intervention for Parents With Cancer
NCT05377749
3-D Super Resolution Ultrasound Microvascular Imaging
NCT04136912
Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials
NCT06361056
Pre-Implementation Study of Improving Thoracic Surgical Care Using Electronic Patient-Reported Outcomes (ePROS)
NCT05311670
Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
NCT05061095
Connecting Audio and Radio Sensing Systems to Improve Care at Home
NCT05344950
Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)
NCT05276622
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 71 |
| Phase 2 | 86 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the UNC Lineberger Comprehensive Cancer Center pipeline
79 recruiting of 366 indexed (22% open); 209 completed (57%).
Phase mix: 2 late (III/IV) vs 157 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
UNC Lineberger Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 366 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
UNC Lineberger Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 366 trials (± recruiting share)
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- University of California, Irvine · 368 trials · 20% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
- Northwell Health · 370 trials · 22% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Women and Infants Hospital of Rhode Island · 22% recruiting · 65 trials
- Merck Sharp & Dohme · 22% recruiting · 558 trials
- Henry M. Jackson Foundation for the Advancement of Military Medicine · 22% recruiting · 60 trials
- AbbVie · 21% recruiting · 526 trials
Related
What to do with this UNC Lineberger Comprehensive Cancer Center page
366 registered trials is a research-attention snapshot, not an endorsement of UNC Lineberger Comprehensive Cancer Center or any single study.
- 79 of UNC Lineberger Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition UNC Lineberger Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
UNC Lineberger Comprehensive Cancer Center pipeline card: 366 registered trials from official public datasets.Report a data error.